ZEVRA THERAPEUTICS, INC. (ZVRA) research
ZEVRA THERAPEUTICS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.99
- As of
ZEVRA THERAPEUTICS, INC. (ZVRA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for ZVRA. Method and limitations.
Share the ZVRA intelligence card
See the full ZVRA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZVRA on one page. Preview it with sample data, then open it live with a free account.
Preview the ZVRA dossierActive signals for ZVRA
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 85% of ZVRA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +578% to ZVRA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 78% of ZVRA (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +54% to ZVRA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 128.3%, EPS $0.25 vs $0.1095 estimate
FREE, NO ACCOUNT
Every signal on ZVRA, as it fires
You are seeing 5 of 11 signals recorded on ZVRA since 2026-05-31.
The five above landed across 2 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZVRA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 488445206 · 2026Q2 | $18.7M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 488445206 · 2026Q2 | $1.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 488445206 · 2026Q2 | $935K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 488445206 · 2026Q2 | $174K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZVRA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ZVRA against its peers
ZVRA's operating margin of -59.1% ranks in the 57th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | ZVRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 106M USD | 10.3M USD | 72 | 15 |
| Gross margin | n/a | 82.6% | n/a | 5 |
| Operating margin | -59.1% | -297.7% | 57 | 14 |
| Net margin | 78.2% | -478.3% | 91 | 15 |
| Return on equity | 53.8% | -41.1% | 98 | 20 |
| P / E | 7.4x | n/a | n/a | 3 |
Peers (23): IRWD, AURA, SLN, CLYM, PHAT, CRMD, SGMT, CTMX, MDXG, STTK, MPLT, ALLO, VALN, NVCT, XOMA, YDES, CAPR, VSTM, PRME, IMMP, ALT, WVE, IMMX. Left out: BLSM (no annual filing), ETRA (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZVRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ZVRA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZVRAand get the insider, 13F, options, and confluence read in one view.